Investor Alert

New York Markets Open in:

May 29, 2020, 3:40 a.m. EDT

Scleroderma Therapeutics Market Clinical Survey Report and Research Outlook 2020-2025

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

May 29, 2020 (Market Insight Reports) --

PatentPicks: Scleroderma Treatments | September 28, 2015 Issue ...

Scleroderma Therapeutics Market – Growth, Trends, and Forecast (2020 – 2025) , This report presents a profound evaluation of basic elements of the Scleroderma Therapeutics industry such as production scale and profit generation. Market driving factors, newly adopted technologies, latest business methodologies have been discussed in this report. The report also forecasts the potential of the market and reviews a thorough analysis of vital segments and regional markets.

Click the link for a Sample Copy of the Report at:

https://www.marketinsightsreports.com/reports/01091744596/scleroderma-therapeutics-market-growth-trends-and-forecast-2020-2025/inquiry?source=mw&Mode=20

Top leading Manufacturers Profiled in Camper Trailers Market Report are Boehringer Ingelheim International GmbH, Celgene Corporation, arGentis Pharmaceuticals, Llc, Prometic Life Sciences Inc., Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Chemomab, Corbus Pharmaceuticals Holdings, Inc., Bayer AG

Scleroderma is a rare and chronic disease that affects around 2.5 million people across the globe. The market for scleroderma therapeutics is expected to grow in the near future owing to the factors such as the rising prevalence of the disease and the focus of pharmaceutical companies to come up with novel drugs.
In the United Kingdom, around 19,000 people were diagnosed with Scleroderma in the year 2018, as stated by Scleroderma & Raynauds UK. In the United Kingdom, Scleroderma & Raynauds UK is the only charity which is dedicated to improving the lives of people suffering from Scleroderma in the country. Studies have suggested that the prevalence of the disease is more in the African Americans and it is 4-9 times higher in women than in men.
Currently, there has been an improvement in the treatment of scleroderma toward managing complications and providing symptomatic relief. Disease-Modifying treatment is widely being investigated for scleroderma which aims at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis. With the upcoming therapies from pharmaceutical companies and future approvals of the same will boost the growth of this market.

Scope of the Report

Scleroderma is an autoimmune disease that affects the skin, blood vessels, muscles, and internal organs. The disease is usually caused due to an abnormal immune response. Therapies for this disease include immunosuppressive drugs and in some cases, glucocorticoids.

Read Detailed Index of full Research Study at:

https://www.marketinsightsreports.com/reports/01091744596/scleroderma-therapeutics-market-growth-trends-and-forecast-2020-2025?source=mw&Mode=20

Immunosuppressors are Expected to Witness High Growth Over the Forecast Period

There is no complete cure for Scleroderma. However, scientists have suggested a few therapies that can be useful for people suffering from this disease. Immunosuppressants are the type of medication that helps reduce the symptoms of scleroderma. As the disease is associated with the immune system, the immunosuppressants help the same by reducing the immune response from occurring. Immunosuppressors act to trigger the death of immune cells or prevent the production of more immune cells. One of the examples for immunotherapy is rituximab which reduces the level of B-cells, a type of immune cells involved in the scleroderma.

As of now, Immunosuppressants are not approved by the FDA for the treatment of scleroderma but they are given to the patients off-label. Some of the immunosuppressants used for scleroderma include Methotrexate, CellCept, Cytoxan, Imuran, cyclosporin, and Thymoglobulin. Several clinical trials are being done currently to investigate the efficacy of immunosuppressants and the results of these clinical trials have suggested that immunosuppressants can be beneficial in treating scleroderma.
Hence, with the growing clinical trials and proven efficacy of the immunosuppressants, their market is expected to grow in the future.

Furthermore, this study will help to solve the following issues:

– Cyclical dynamics: Report foresees the dynamics of industries by using core analytical and unconventional market research approaches.

– Identifying key cannibalizes: Strong substitute for a product or service is the most prominent threat. The report includes key cannibalizes of a market, by procuring marketing research. This helps in aligning new product development/launch strategies before.

– Spotting emerging trends: Report helps to identify upcoming hot market trends. The report also tracks possible impact and disruptions which a market would witness by a specific emerging trend.

– Interrelated opportunities: This report will allow making decisions based on data, thereby increasing the chances that the strategies will perform better.

Note: All the reports that we list have been tracking the impact of COVID-19 on the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

CONTACT US:

Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

COMTEX_366266980/2599/2020-05-29T03:39:45

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.